LGND

Ligand Pharmaceuticals Inc.

202.60

USD

LGND Earnings Reports

Positive Surprise Ratio

LGND beat 37 of 40 last estimates.

93%

Next Report

Date of Next Report

May 06, 2026

Estimate for Q1 26 (Revenue/ EPS)

$59.66M

$1.78

Implied change from Q4 25 (Revenue/ EPS)

-0.02%

-11.88%

Implied change from Q1 25 (Revenue/ EPS)

+31.60%

+33.83%

Ligand Pharmaceuticals Inc. earnings per share and revenue

On Feb 26, 2026, LGND reported earnings of 2.02 USD per share (EPS) for Q4 25, beating the estimate of 1.59 USD, resulting in a 26.84% surprise. Revenue reached 59.67 million, compared to an expected 56.70 million, with a 5.23% difference. The market reacted with a +2.50% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 5 analysts forecast an EPS of 1.78 USD, with revenue projected to reach 59.66 million USD, implying an decrease of -11.88% EPS, and decrease of -0.02% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Mineralys Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.54

Actual

-$0.40

Surprise

+26.40%

Corvus Pharmaceuticals, Inc.

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.13

Actual

-$0.15

Surprise

-13.72%

Pharming Group N.V. ADS, each representing 10 ordinary shares

Report Date

Mar 12, 2026 For Q4 25

Estimate

$0.00

Actual

$0.01

Surprise

+16.28%

ADC Therapeutics SA

Report Date

Mar 10, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.04

Surprise

+85.39%

Kamada Ltd

Report Date

Mar 11, 2026 For Q4 25

Estimate

$0.07

Actual

$0.06

Surprise

-24.15%

Allogene Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.22

Actual

-$0.17

Surprise

+22.73%

Molecular Partners AG - ADR

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.34

Actual

-$0.32

Surprise

+7.09%

Whitehawk Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.15

Actual

-$0.34

Surprise

-116.42%

Codexis, Inc.

Report Date

Mar 11, 2026 For Q4 25

Estimate

-$0.04

Actual

$0.11

Surprise

+357.01%

Spruce Biosciences, Inc. Common Stock

Report Date

Apr 13, 2026 For Q4 25

Estimate

-$8.14

Actual

Surprise

FAQ

What were Ligand Pharmaceuticals Inc.'s earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Ligand Pharmaceuticals Inc. reported EPS of $2.02, beating estimates by 26.84%, and revenue of $59.67M, 5.23% above expectations.

How did the market react to Ligand Pharmaceuticals Inc.'s Q4 2025 earnings?

The stock price moved up 2.5%, changed from $191.39 before the earnings release to $196.17 the day after.

When is Ligand Pharmaceuticals Inc. expected to report next?

The next earning report is scheduled for May 06, 2026.

What are the forecasts for Ligand Pharmaceuticals Inc.'s next earnings report?

Based on 5 analysts, Ligand Pharmaceuticals Inc. is expected to report EPS of $1.78 and revenue of $59.66M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.